Kronos Bio Signs a Multi-Year Collaboration with Tempus for Access to its Platform
Shots:
- Kronos will receive access to Tempus real-world data & tools to expand its preclinical/clinical development portfolio & retains an option to join Tempus TIME trial network to support patient identification, site activation & enrollment of selected clinical trials
- The new collaboration follows an earlier agreement & will utilize Kronos Bio's expertise in transcriptional regulation & Tempus sequencing capabilities along with both company's computational biology capabilities to advance the clinical program's portfolio including lanraplenib & KB-0742
- Additionally, Tempus will harness the strength of its platform to support the discovery and development of novel cancer therapeutics
Ref: Globe Newswire | Image: Kronos
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com